Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 377

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 4
Chunk 377
---
 four treatment guidelines and consensus recommendations: CSCO Guidelines for Lymphoid Malignancies, CSCO Guidelines for Bone and Soft Tissue Sarcoma, CACA Expert Consensus on Diagnosis and Treatment of Follicular Lymphoma in Elderly Patients in China and CACA Guidelines for Diagnosis and Treatment of Follicular Lymphoma in China. While not approved by the NMPA or included in the NRDL coverage yet, it has been listed in close to 50 city supplementary healthcare insurance.
Ten epithelioid sarcoma patients began treatment in 2024 (2023: 16, 2022: 3). Tazverik was also approved in the Macau Special Administrative Region in March 2023 and Hong Kong Special Administrative Region in May 2024. In July 2024, the NDA for tazemetostat for the treatment of adult patients with 3L r/r EZH2m FL was accepted for review and granted Priority Review by the NMPA. We are also taking part in the China portion of the global SYMPHONY-1 Phase III study of tazemetostat in combination with lenalidomide and rituximab in 2L FL. In-market shares and consolidated revenue were around 1.0 million each year last two years.
​

Clinical Drug Development Summary
We discovered and developed all our the innovative drugs in our pipeline, except tazemetostat, which we in-licensed from Epizyme, a subsidiary of Ipsen. We partner with Eli Lilly marketing fruquintinib in China, and with Takeda outside of China. We partner globally with AstraZeneca for savolitinib. Please see details in “—Overview of Our Collaborations—.” We retain the global rights to the rest of the portfolio.
<{self.tag} alt="{self.alt}" src="{self.src}">The following table summarizes the status of our clinical portfolio’s development in registrational trials:
​
* Phase II registration-intent study subject to regulatory discussion; ** Phase II part of the Phase II/III study 
Notes: AML: acute myeloid leukemia; CRC: colorectal cancer; CSF-1R: colony-stimulating factor 1 receptor; EGFR: epidermal growth factor receptor; EGFRm: epidermal growth factor receptor mutation-positive; EMC: endometrial cancer; ES: Epithelioid sarcoma; EZH2: enhancer of